CD22 Antibody (OX96): sc-53031
- CD22 Antibody (OX96) is a rat monoclonal IgG1 provided at 200 µg/ml
- raised against CD22 of mouse origin
- recommended for detection of CD22 of mouse origin by FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for CD22 Antibody (OX96). This work is in progress.
QUICK LINKS
SEE ALSO...
CD22 Antibody (OX96) is a rat monoclonal IgG1 antibody that detects CD22 in mouse samples through flow cytometry (FCM). CD22 is a crucial B lymphocyte-specific antigen, also known as the B-lymphocyte cell adhesion molecule (BLCAM), sialic acid-binding Ig-like lectin 2 (Siglec-2), and Leu-14. This type I integral membrane glycoprotein plays a vital role in regulating B cell signaling, which is essential for maintaining immune homeostasis and preventing autoimmune responses. CD22 is expressed in both cytoplasmic and membrane forms during various stages of B cell differentiation, with the cytoplasmic variant serving as a significant marker for acute lymphocytic leukemia, particularly in early B cell development. The membrane form is predominantly found in mature B cells before differentiation into plasma cells, highlighting CD22′s importance in the maturation process. Alternative splicing of the CD22 gene results in two isoforms, CD22α and CD22β, with CD22β being the principal isoform. CD22 can exist as a heterodimer composed of CD22β and the shorter CD22α isoform, which may influence functional properties and interactions with other proteins. Anti-CD22 antibody (OX96) is an invaluable tool for researchers studying B cell biology and related pathologies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD22 Antibody (OX96) References:
- Receptor modulators of B-cell receptor signalling--CD19/CD22. | Smith, KG. and Fearon, DT. 2000. Curr Top Microbiol Immunol. 245: 195-212. PMID: 10533314
- CD22-directed monoclonal antibody therapy for lymphoma. | Siegel, AB., et al. 2003. Semin Oncol. 30: 457-64. PMID: 12939714
- Characterization of CD22 expression in acute lymphoblastic leukemia. | Shah, NN., et al. 2015. Pediatr Blood Cancer. 62: 964-9. PMID: 25728039
- CD19/CD22 Dual-Targeted CAR-T Therapy Active in Relapsed/Refractory DLBCL. | . 2020. Oncologist. 25 Suppl 1: S12-S13. PMID: 32589304
- Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia. | Zhang, T., et al. 2022. Transpl Immunol. 71: 101538. PMID: 35051588
- Notch1-CD22-Dependent Immune Dysregulation in the SARS-CoV2-Associated Multisystem Inflammatory Syndrome in Children. | Chatila, TA., et al. 2022. Res Sq.. PMID: 35441180
- Targeting Human CD22/Siglec-2 with Dimeric Sialosides as Novel Oligosaccharide Mimetics. | Prescher, H., et al. 2022. J Med Chem. 65: 10588-10610. PMID: 35881556
- Improved synthesis of CD22-binding sialosides and its application for further development of potent CD22 inhibitors. | Suganuma, Y., et al. 2023. Glycoconj J. 40: 225-246. PMID: 36708410
- CD22 Exon 12 Deletion as an Independent Predictor of Poor Treatment Outcomes in B-ALL. | Qazi, S. and Uckun, FM. 2023. Cancers (Basel). 15: PMID: 36900389
- Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review. | Becerril-Rico, J., et al. 2023. Leuk Lymphoma. 64: 1822-1831. PMID: 37548560
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD22 Antibody (OX96) | sc-53031 | 200 µg/ml | $322.00 | |||
CD22 Antibody (OX96) FITC | sc-53031 FITC | 200 µg/ml | $336.00 | |||
CD22 Antibody (OX96) PE | sc-53031 PE | 200 µg/ml | $349.00 |